Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Dianjing Biomedical Technology (Suzhou)

Request full access

Developing innovative ocular and recombinant human collagen-based therapeutics

Huangpu, ChinaFounded 2020Biotech & Life Sciences

About Dianjing Biomedical Technology (Suzhou)

Eluminex Biosciences is a clinical-stage biotechnology firm that specializes in the research and development of innovative therapeutics. The company's primary focus is on ophthalmology and recombinant human collagen technology. In simpler terms, they are working on advanced treatments for eye conditions and therapies based on human collagen, a protein that provides structure to various body parts.

The company operates in the global healthcare market, with a significant emphasis on China. Their business model revolves around the development and commercialization of their therapeutics. They generate revenue through the successful launch and sales of these treatments, as well as through strategic partnerships and financing rounds.

Eluminex has recently secured over $40 million in Series B financing, following an initial $50 million Series A financing in 2020. This funding will allow the company to further develop its innovative pipeline of treatments and initiate additional clinical-stage projects. The company has also completed a B+ round of financing, raising more than $50 million in venture capital in 2023 alone. This funding will be used to advance multiple preclinical and clinical programs rapidly.

In summary, Eluminex Biosciences is a promising biotech startup, making significant strides in the development of innovative ocular and collagen-based therapeutics. Their recent successful financing rounds demonstrate strong investor confidence and provide the necessary capital to continue their research and development efforts.

Source: Dealroom company data

At a glance

Status
Operational
Employees
12
Open positions
None listed
Dealroom signal
60.6/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, proteomics, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

3 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Aug 2023 $10M $250M Oriza FOFs · Suzhou International Development Venture Capital Holding ↗
SERIES BOther financing Feb 2023 $40M $250M Oriza Holdings · Cenova Capital · Lilly Asia Ventures · Quan Capital ↗
Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Dianjing Biomedical Technology (Suzhou) website traffic

Latest recorded traffic for Dianjing Biomedical Technology (Suzhou) is 610 monthly website visits, up 1933.3% over the last three months. Dianjing Biomedical Technology (Suzhou)'s team grew 0% over the past year.

Latest monthly visits610 3-month web change+1933.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Dianjing Biomedical Technology (Suzhou) in the Huangpu ecosystem

Live from Dealroom

The Dianjing Biomedical Technology (Suzhou) office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Lilly Asia Ventures
  • Quan Capital
  • GL Ventures
  • Cenova Capital
  • Oriza Holdings
  • Guangzhou YUEXIU Industrial Investment Fund
  • 3E Bioventures
  • Oriza FOFs
  • Suzhou International Development Venture Capital Holding
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇨🇳 China50%
🇺🇸 United States50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Dianjing Biomedical Technology (Suzhou) on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Dianjing Biomedical Technology (Suzhou)’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.